HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network
Menée à partir de données de vie réelle portant sur 927 patients atteints d'un lymphome hodgkinien diagnostiqué entre 2015 et 2025, cette étude de cohorte rétrospective évalue l'association entre une infection par le VIH et la survie
Despite effective antiretroviral therapy, people living with human immunodeficiency virus (HIV) (PLWH) remain at a higher risk of developing Hodgkin lymphoma (HL). Further, survival disparities persist despite similar treatment recommendations. Herein, we present a global retrospective cohort study including data of adult (≥18 years) diagnosed with HL between 2015 and 2025 from the TriNetX database to evaluate the survival outcomes of Hodgkin lymphoma in HIV-infected versus non-HIV-infected patients and analyze the associated risk factors. Patients were stratified according to HIV status and matched 1:1 for age, sex, race, and comorbidities. Overall survival (OS) was analyzed using Kaplan–Meier and Cox proportional hazards models. A total of 927 matched HIV-infected and non-HIV-infected patients were included. Overall, HIV-positive status was associated with significantly inferior OS (HR 1.42; 95% CI 1.10–1.84; p = 0.033). Among PLWH, cerebrovascular disease, hepatitis C virus infection, and chronic kidney disease independently predicted increased mortality. In a matched subgroup of patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy (n = 154 per group), OS did not differ significantly between HIV-positive and HIV-negative groups (HR 1.37; 95% CI 0.73–2.56; p = 0.247). In conclusion, HIV-infected patients with HL experienced worse OS compared with non-HIV-infected individuals, but the outcomes were comparable when treated with ABVD chemotherapy, highlighting the importance of optimal treatment delivery and comorbidity management in PLWH.
JNCI Cancer Spectrum , résumé, 2026